SBFM (Sunshine Biopharma) צמיחת הכנסות מרבעון לרבעון

Sunshine Biopharma (SBFM) relies on a dedicated staff of oncologists while actively recruiting foreign compliance experts. Drug production is fully outsourced to contract manufacturing organizations (CMO). Financial stability remains low, as development depends on new investments. This chart of quarterly revenue growth reflects current dynamics, with the indicator holding around 0.30.
פילוחי מדדים פיננסיים ומדדי שוק עבור Sunshine Biopharma (SBFM)

Quarterly revenue growth measures the rate of change in operating income over a three-month period, allowing for an assessment of the business's fundamental momentum and the risk of asset impairment should sales slow. By analyzing quarterly sales dynamics, an investor can track the commercial efficiency of Sunshine Biopharma (SBFM) within the anti-adhesive drug segment, evaluating the company's ability to scale deliveries to oncology centers to block tumor metastasis.